Atıf Formatları
PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

E. B. Eniseler Et Al. , "PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy," Nuclear Medicine Communications , 2026

Eniseler, E. B. Et Al. 2026. PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy. Nuclear Medicine Communications .

Eniseler, E. B., EKİNCİ, F., ŞAHBAZLAR, M., & ERDOĞAN, A. P., (2026). PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy. Nuclear Medicine Communications .

Eniseler, Emine Et Al. "PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy," Nuclear Medicine Communications , 2026

Eniseler, Emine B. Et Al. "PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy." Nuclear Medicine Communications , 2026

Eniseler, E. B. Et Al. (2026) . "PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy." Nuclear Medicine Communications .

@article{article, author={Emine Bihter Eniseler Et Al. }, title={PET-derived metabolic–immunonutritional SUVmax–lactate dehydrogenase–albumin–lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy}, journal={Nuclear Medicine Communications}, year=2026}